GlassScriptPhysician profile
Chittaranjan Patel
NPI 1477660801
$882.50
in general payments reported to CMS, 2019-2025
19 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.59 · 2020: $35.68 · 2021: $201 · 2022: $194 · 2023: $178 · 2024: $120 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $435.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $228.90 | 2022-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $97.96 | 2020-2022 | |
| Abbvie INC. | $73.36 | 2021-2025 | |
| Dexcom, INC. | $72.02 | 2021-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $61.43 | 2022-2025 | |
| Glaxosmithkline, LLC. | $51.62 | 2022-2024 | Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $50.28 | 2021 | |
| Pfizer INC. | $37.56 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $31.08 | 2023-2024 | Verquvo, Steglatro, Belsomra |
| Janssen Pharmaceuticals, INC | $26.44 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $23.25 | 2025 | Evkeeza |
| Alkermes, INC. | $22.62 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.17 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $16.57 | 2022 | |
| Amneal Pharmaceuticals LLC | $16.42 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $15.59 | 2019 | |
| Phadia US INC. | $14.44 | 2022 | |
| Abbott Laboratories | $13.76 | 2023 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $12.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chittaranjan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.